Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$102.89 +1.3%	$106.56	$72.02 ▼ $139.13	$5.00B	0.47	677,064 shs	650,414 shs
JANX Janux Therapeutics	$22.72 -0.8%	$26.86	$22.48 ▼ $71.71	$1.36B	2.96	870,163 shs	660,534 shs
LNTH Lantheus	$78.99 +1.4%	$87.64	$73.11 ▼ $126.89	$5.39B	0.11	1.02 million shs	942,075 shs
NUVL Nuvalent	$75.53 -0.7%	$73.55	$55.54 ▼ $113.51	$5.46B	1.34	493,725 shs	360,890 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.27%	-4.80%	-5.00%	-18.52%	+35.35%
JANX Janux Therapeutics	-0.83%	-10.76%	-6.00%	-25.34%	-43.76%
LNTH Lantheus	+1.37%	-2.18%	+0.95%	-20.09%	-2.64%
NUVL Nuvalent	-0.70%	-1.79%	+3.03%	-2.72%	-3.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7477 of 5 stars	4.5	2.0	4.5	2.3	4.2	0.6
JANX Janux Therapeutics	2.2735 of 5 stars	3.5	2.0	0.0	2.1	2.5	0.0
LNTH Lantheus	4.3412 of 5 stars	3.5	1.0	4.2	2.1	2.5	1.9
NUVL Nuvalent	2.4743 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.49% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	319.23% Upside
LNTH Lantheus	3.00	Buy	$132.67	67.95% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	52.92% Upside

Current Analyst Ratings Breakdown

Latest JANX, NUVL, LNTH, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/7/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$200.00 ➝ $180.00
5/6/2025	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $165.00
5/6/2025	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$160.00 ➝ $162.00
4/29/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$190.00 ➝ $193.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.14	N/A	N/A	$1.18 per share	87.19
JANX Janux Therapeutics	$10.59M	126.94	N/A	N/A	$19.49 per share	1.17
LNTH Lantheus	$1.53B	3.56	$7.19 per share	10.98	$15.65 per share	5.05
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.49	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	-463.91%	-9.29%	-8.89%	8/6/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.44	12.52	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)

Latest JANX, NUVL, LNTH, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
JANX Janux Therapeutics	N/A	58.47	58.47
LNTH Lantheus	0.49	5.74	5.46
NUVL Nuvalent	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JANX Janux Therapeutics	75.39%
LNTH Lantheus	99.06%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
JANX Janux Therapeutics	8.10%
LNTH Lantheus	1.50%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable

JANX, NUVL, LNTH, and AXSM Headlines

Recent News About These Companies

Nuvalent Appoints Christy Oliger to Board of Directors

June 18 at 4:30 PM | prnewswire.com

GAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL)

June 18 at 3:13 AM | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Receives $115.50 Consensus PT from Brokerages

June 18 at 2:47 AM | americanbankingnews.com

Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock

June 15, 2025 | investing.com

Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 15, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 200 Shares

June 11, 2025 | insidertrades.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 200 Shares of Stock

June 10, 2025 | marketbeat.com

Nuvalent Board Member Emily Conley Resigns

June 10, 2025 | tipranks.com

California State Teachers Retirement System Purchases 5,109 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

June 6, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Nuvalent, Inc. (NASDAQ:NUVL)

June 2, 2025 | marketbeat.com

Nuvalent, Inc. Reports Q1 2025 Financial Results

May 31, 2025 | tipranks.com

Nuvalent (NASDAQ:NUVL) Stock Price Up 6.2% - Time to Buy?

May 30, 2025 | marketbeat.com

Squarepoint Ops LLC Reduces Position in Nuvalent, Inc. (NASDAQ:NUVL)

May 29, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Polar Asset Management Partners Inc.

May 28, 2025 | marketbeat.com

Voloridge Investment Management LLC Has $13.37 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL)

May 26, 2025 | marketbeat.com

Two Sigma Advisers LP Decreases Stake in Nuvalent, Inc. (NASDAQ:NUVL)

May 25, 2025 | marketbeat.com

Two Sigma Investments LP Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL)

May 25, 2025 | marketbeat.com

Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year

May 24, 2025 | investing.com

Twinbeech Capital LP Invests $2.32 Million in Nuvalent, Inc. (NASDAQ:NUVL)

May 24, 2025 | marketbeat.com

Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)

May 24, 2025 | marketbeat.com

Man Group plc Purchases 41,447 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, NUVL, LNTH, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$102.89 +1.29 (+1.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$101.66 -1.22 (-1.19%)

As of 06/18/2025 07:31 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Janux Therapeutics NASDAQ:JANX

$22.72 -0.19 (-0.83%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$22.75 +0.03 (+0.13%)

As of 06/18/2025 06:21 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Lantheus NASDAQ:LNTH

$78.99 +1.07 (+1.37%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$79.62 +0.63 (+0.80%)

As of 06/18/2025 07:29 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent NASDAQ:NUVL

$75.53 -0.53 (-0.70%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$75.55 +0.02 (+0.03%)

As of 06/18/2025 04:39 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time